Conestoga Capital Advisors LLC Has $149.41 Million Stake in Merit Medical Systems, Inc. $MMSI

Conestoga Capital Advisors LLC grew its position in Merit Medical Systems, Inc. (NASDAQ:MMSI) by 3.9% in the first quarter, HoldingsChannel.com reports. The fund owned 2,167,513 shares of the medical instruments supplier’s stock after buying an additional 81,030 shares during the quarter. Merit Medical Systems comprises 3.0% of Conestoga Capital Advisors LLC’s portfolio, making the stock its 11th biggest position. Conestoga Capital Advisors LLC’s holdings in Merit Medical Systems were worth $149,407,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also modified their holdings of the business. Tudor Investment Corp ET AL bought a new position in Merit Medical Systems in the 3rd quarter valued at $2,913,050,000. SG Americas Securities LLC bought a new stake in shares of Merit Medical Systems during the fourth quarter worth $1,537,000. Bessemer Group Inc. increased its stake in shares of Merit Medical Systems by 54.2% in the fourth quarter. Bessemer Group Inc. now owns 313,981 shares of the medical instruments supplier’s stock valued at $27,674,000 after buying an additional 110,392 shares in the last quarter. JPMorgan Chase & Co. raised its holdings in shares of Merit Medical Systems by 7.6% in the third quarter. JPMorgan Chase & Co. now owns 917,122 shares of the medical instruments supplier’s stock valued at $76,332,000 after buying an additional 64,920 shares during the last quarter. Finally, WINTON GROUP Ltd bought a new position in shares of Merit Medical Systems in the fourth quarter valued at about $12,239,000. 99.66% of the stock is owned by institutional investors and hedge funds.

Merit Medical Systems Stock Up 0.2%

Shares of NASDAQ:MMSI opened at $69.45 on Thursday. Merit Medical Systems, Inc. has a one year low of $59.74 and a one year high of $96.74. The company has a 50 day moving average of $65.35 and a 200-day moving average of $73.78. The company has a debt-to-equity ratio of 0.45, a current ratio of 5.08 and a quick ratio of 3.46. The stock has a market cap of $4.14 billion, a price-to-earnings ratio of 30.07, a P/E/G ratio of 2.16 and a beta of 0.51.

Merit Medical Systems (NASDAQ:MMSI) last announced its quarterly earnings data on Thursday, April 30th. The medical instruments supplier reported $0.94 earnings per share for the quarter, beating the consensus estimate of $0.84 by $0.10. Merit Medical Systems had a net margin of 9.03% and a return on equity of 13.54%. The business had revenue of $381.88 million for the quarter, compared to analyst estimates of $377.59 million. During the same period in the prior year, the business posted $0.86 earnings per share. Merit Medical Systems’s revenue was up 7.4% compared to the same quarter last year. Merit Medical Systems has set its FY 2026 guidance at 4.010-4.150 EPS. On average, sell-side analysts forecast that Merit Medical Systems, Inc. will post 3.62 earnings per share for the current year.

Analyst Ratings Changes

Several equities research analysts have weighed in on MMSI shares. Citigroup restated an “outperform” rating on shares of Merit Medical Systems in a research report on Monday, April 20th. Wall Street Zen lowered shares of Merit Medical Systems from a “strong-buy” rating to a “buy” rating in a report on Sunday, April 5th. Weiss Ratings cut shares of Merit Medical Systems from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Friday, May 8th. JPMorgan Chase & Co. reduced their price objective on Merit Medical Systems from $95.00 to $77.00 and set an “overweight” rating on the stock in a report on Friday, May 1st. Finally, Compass Point set a $107.00 price objective on Merit Medical Systems in a research report on Monday, April 20th. Eight analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, Merit Medical Systems presently has a consensus rating of “Moderate Buy” and a consensus price target of $92.80.

Insiders Place Their Bets

In related news, Director Lynne N. Ward sold 5,000 shares of Merit Medical Systems stock in a transaction on Thursday, May 7th. The stock was sold at an average price of $62.61, for a total transaction of $313,050.00. Following the completion of the sale, the director directly owned 7,809 shares of the company’s stock, valued at $488,921.49. The trade was a 39.04% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider Brian G. Lloyd acquired 2,000 shares of the company’s stock in a transaction that occurred on Thursday, May 7th. The stock was bought at an average price of $62.62 per share, with a total value of $125,240.00. Following the acquisition, the insider directly owned 2,000 shares of the company’s stock, valued at $125,240. The trade was a ∞ increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Corporate insiders own 0.70% of the company’s stock.

Merit Medical Systems Company Profile

Merit Medical Systems, Inc is a global manufacturer and marketer of a broad range of medical devices used in diagnostic and interventional procedures. The company’s product portfolio encompasses vascular access, drainage, embolotherapy, and interventional oncology devices, as well as radiofrequency ablation systems and hemostasis solutions. These products serve physicians and hospitals in critical care settings and support minimally invasive treatment options across multiple specialties, including cardiology, radiology, oncology, neurology and endoscopy.

Founded in 1987 by Fred Lampropoulos, Merit Medical Systems has grown through both organic development and targeted acquisitions to expand its technology offerings and geographic reach.